Jagsonpal Pharmaceuticals Limited has announced a conference call with analysts and investors to discuss its Q4 FY26 financial results. The jagsonpal pharmaceuticals informed both BSE and NSE about this scheduled investor engagement activity on April 22, 2026, in compliance with regulatory requirements.

Conference Call Details

The earnings conference call has been scheduled for the following date and time:

Regulatory Compliance

The company has notified stock exchanges about this investor engagement activity pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was sent to both major stock exchanges where the company is listed.

Participation Information

Jagsonpal Pharmaceuticals has provided comprehensive details for participants interested in joining the conference call:

• Pre-registration: Available through a dedicated registration link to avoid wait times
• Dial-in numbers: +91 22 6280 1557 / +91 22 7115 8383
• Recommended timing: Participants advised to dial-in 5-10 minutes prior to scheduled time
• Diamond Pass: Available for registered participants to ensure smooth connectivity

Company Representatives

The conference call will feature key management personnel from Jagsonpal Pharmaceuticals, including senior executives who will present the Q4 FY26 financial performance and address queries from analysts and investors. Go India Advisors is facilitating the conference call as the hosting partner.

Contact Information

For additional information regarding the conference call, participants can reach out to the designated contacts at Go India Advisors: Soumya Chhajed and Sheetal Khanduja. The company secretary Pratham Rawal signed the official communication to stock exchanges regarding this announcement.

Jagsonpal Pharmaceuticals Limited has announced the successful allotment of 1,76,900 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) to eligible employees. The allotment was completed on April 13, 2026, following the exercise of vested options by company employees.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's paid-up share capital. The following table shows the capital structure before and after the allotment:

Exercise Price Structure

The ESOP shares were allotted at three different exercise price levels, reflecting the varying grant dates and market conditions at the time of option grants:

Regulatory Compliance and Share Details

The company has fulfilled all regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly allotted shares carry distinctive numbers from 6,69,62,251 to 6,71,39,150 and will be issued in demat form.

Key regulatory aspects include:

• The shares rank pari passu with existing equity shares in all respects
• No lock-in period applies to the allotted shares
• The company's shares are listed on BSE Limited and National Stock Exchange of India Limited
• Original ESOP filing was completed in July 2022 with both exchanges

Corporate Structure

Jagsonpal Pharmaceuticals Limited, incorporated in 1978, operates from its corporate office in Gurugram, Haryana, with its registered office located in New Delhi. The company maintains additional operational presence in Mumbai, Maharashtra. The allotment was approved by the Nomination and Remuneration Committee and executed by Company Secretary Pratham Rawal.

The successful completion of this ESOP allotment demonstrates the company's commitment to employee participation in its growth story while strengthening its equity base through internal capital generation.